The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 601–700 of 1,056
Therapeutic monoclonal antibodies in ophthalmology
Rodrigues, E. B., Farah, M. E., Maia, M., Penha, F. M., Regatieri, C., Melo, G. B., Pinheiro, M. M., & Zanetti, C. R. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.005 · Cited by 173
“VEGF is a family of proteins that includes placenta growth factor (PlGF), VEGF-A, VEGF-B, VEGF-C, VEGF-D and the viral VEGF homologue VEGF-E (Ferrara et al., 2001, 2003).”
Salameh, A., Galvagni, F., Bardelli, M., Bussolino, F., & Oliviero, S. (2005) · Blood · doi:10.1182/blood-2005-04-1388 · Cited by 173
“(E) HUVEC extracts assayed for JNK-dependent kinase activity toward recombinant GST–c-JUN 1-79 in vitro by phosphorylation of serine 63 and 73 with phosphospecific antibodies.”
MethodInfluentialHypoxia‐mediated biological control
Cassavaugh, J., & Lounsbury, K. M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22956 · Cited by 169
“The serine proteases degrade the microenvironment and allow sprouting endothelial cells to migrate into the hypoxic tissue [Pepper et al., 1991; Ferrara et al., 2003].”
BackgroundSkerra, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06439.x · Cited by 176
Tuder, R. M., Yoshida, T., Arap, W., Pasqualini, R., & Petrache, I. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200603-054ms · Cited by 174
“VEGF represents a family of ligands (A–D), which bind to three sets of receptors (VEGF-R1, VEGF-R2, and VEGF-R3) (20).”
BackgroundHypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors
Chen, L., Endler, A., & Shibasaki, F. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.12.103 · Cited by 164
“One of the angiogenic factors, VEGF, has been reported to be the most remarkable one stimulating angiogenesis in a strictly dose-dependent manner (Ferrara et al., 2003).”
BackgroundEngineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis
Zhu, T., Cui, Y., Zhang, M., Zhao, D., Liu, G., & Ding, J. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.04.008 · Cited by 178
“Vascular endothelial growth factor (VEGF) is regarded as a critical regulator of physiological angiogenesis during bone growth and reconstruction [128].”
BackgroundMurakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y., & Shibuya, M. (2006) · Blood · doi:10.1182/blood-2006-04-016030 · Cited by 166
Dental pulp stem cells in regenerative dentistry
Casagrande, L., Cordeiro, M. M., Nör, S. A., & Nör, J. E. (2011) · Odontology · doi:10.1007/s10266-010-0154-z · Cited by 167
“In vivo, VEGF enhances permeability and induces potent proangiogenic responses.(65,66) Notably, VEGF plays a critical role in the regulation of angiogenesis by enhancing endothelial cell survival.”
BackgroundAutocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion
Perrot-Applanat, M., & Di Benedetto, M. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.23332 · Cited by 170
“Cellular responses to VEGF165 are mediated by two highaffinity type III tyrosine kinase receptors, VEGF-R2 (KDR/ Flk1) and VEGF-R1 (Flt-1), and two receptors of the semaphorin receptor family, neuropilin-1 and neuropilin-2.(9,10) Initially, VEGF-A (VEGF165) was believed to act exclusively on”
BackgroundAntiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
de Boüard, S., Herlin, P., Christensen, J. G., Lemoisson, E., Gauduchon, P., Raymond, E., & Guillamo, J.-S. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-024 · Cited by 180
Jonsson, P. F., Cavanna, T., Zicha, D., & Bates, P. A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-2 · Cited by 178
“…vascular endothelial growth factors (Vegfa, Vegfc, Figf) and the receptor (Kdr), which play a principle role in tumour progression and angiogenesis [32] and which have also been associated with tumour metastasis [33]; insulin-like growth factors and receptors (Igf1, Igf1r and Grb 7/14); and…”
BackgroundZinc oxide nanoflowers make new blood vessels
Barui, A. K., Veeriah, V., Mukherjee, S., Manna, J., Patel, A. K., Patra, S., Pal, K., Murali, S., Rana, R. K., Chatterjee, S., et al. (2012) · Nanoscale · doi:10.1039/c2nr32369a · Cited by 172
Diabetic retinopathy: Breaking the barrier
Eshaq, R. S., Aldalati, A. M. Z., Alexander, J. S., & Harris, N. R. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.07.001 · Cited by 169
“predominant isoform with the most functional bioavailability [168].”
BackgroundInnovative Biomaterials for Bone Regrowth
Iaquinta, M. R., Mazzoni, E., Manfrini, M., D’Agostino, A., Trevisiol, L., Nocini, R., Trombelli, L., Barbanti-Brodano, G., Martini, F., & Tognon, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030618 · Cited by 165
“Moreover, it plays an important role in the promotion of permeability and fenestration of blood vessels [136].”
BackgroundNon-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic
de Groot, D. J. A., de Vries, E. G. E., Groen, H. J. M., & de Jong, S. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.07.001 · Cited by 175
“[47] Ferrara N, Gerber HP, LeCouter J.”
Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis
Calvo, C.-F., Fontaine, R. H., Soueid, J., Tammela, T., Makinen, T., Alfaro-Cervello, C., Bonnaud, F., Miguez, A., Benhaim, L., Xu, Y., et al. (2011) · Genes & Development · doi:10.1101/gad.615311 · Cited by 171
“…development (Sondell et al. 2000; Louissaint et al. 2002; Zhang et al. 2003; Wada et al. 2006; Wittko et al. 2009), and represent potential therapeutic tools for neural tissue repair and neurodegenerative diseases (Ferrara et al. 2003; Storkebaum et al. 2004; Ruiz de Almodovar et al. 2009).”
BackgroundLabler, L., Rancan, M., Mica, L., Härter, L., Mihic-Probst, D., & Keel, M. (2009) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e318171971a · Cited by 172
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease
Monks, D. A., Johansen, J. A., Mo, K., Rao, P., Eagleson, B., Yu, Z., Lieberman, A. P., Breedlove, S. M., & Jordan, C. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705501104 · Cited by 171
The Role of Cyclooxygenase-2 in Colorectal Cancer
Sheng, J., Sun, H., Yu, F.-B., Li, B., Zhang, Y., & Zhu, Y.-T. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.44439 · Cited by 164
“Suppression of COX-2 inhibits corneal neovascularization in colorectal cancer [81] by promoting production of angiogenic vascular endothelial growth factor (VEGF), a potent angiogenic growth factor [82].”
BackgroundThe Adverse Effects of Sorafenib in Patients with Advanced Cancers
Li, Y., Gao, Z., & Qu, X. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12365 · Cited by 170
Leslie-Barbick, J. E., Moon, J. J., & West, J. L. (2009) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856208x386381 · Cited by 171
Zhang, R., Xu, Y., Ekman, N., Wu, Z., Wu, J., Alitalo, K., & Min, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310678200 · Cited by 163
Ottaiano, A., Franco, R., Aiello Talamanca, A., Liguori, G., Tatangelo, F., Delrio, P., Nasti, G., Barletta, E., Facchini, G., Daniele, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2142 · Cited by 171
Tumor-derived factors modulating dendritic cell function
Zong, J., Keskinov, A. A., Shurin, G. V., & Shurin, M. R. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1820-y · Cited by 164
Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia
Khurana, R., Zhuang, Z., Bhardwaj, S., Murakami, M., De Muinck, E., Yla-Herttuala, S., Ferrara, N., Martin, J. F., Zachary, I., & Simons, M. (2004) · Circulation · doi:10.1161/01.cir.0000145138.25577.f1 · Cited by 169
Self-citationAnti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice
Hamada, N., Kuwano, K., Yamada, M., Hagimoto, N., Hiasa, K., Egashira, K., Nakashima, N., Maeyama, T., Yoshimi, M., & Nakanishi, Y. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.1224 · Cited by 170
Ha, C. H., Wang, W., Jhun, B. S., Wong, C., Hausser, A., Pfizenmaier, K., McKinsey, T. A., Olson, E. N., & Jin, Z.-G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800264200 · Cited by 170
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
“To further investigate the role of CD11b+Gr1+ cells in refractoriness to anti-VEGF, we also treated the same tumors with mFlt(1-3)-IgG, a high affinity chimeric-soluble VEGFR-1 variant that not only neutralizes VEGF-A but also PlGF and VEGF-B (23).”
BackgroundSelf-citationCardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.006 · Cited by 166
Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J. A., & Zisch, A. H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.018 · Cited by 171
Reddy, S. K., Morse, M. A., Hurwitz, H. I., Bendell, J. C., Gan, T. J., Hill, S. E., & Clary, B. M. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.06.290 · Cited by 172
Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis
Baniwal, S. K., Khalid, O., Gabet, Y., Shah, R. R., Purcell, D. J., Mav, D., Kohn-Gabet, A. E., Shi, Y., Coetzee, G. A., & Frenkel, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-258 · Cited by 169
“5E-10 5 3 4 Growth factor, angiogenesis, cellular morphogenesis during differentiation [88-91]”
BackgroundPhage‐Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine
Sunderland, K. S., Yang, M., & Mao, C. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201606181 · Cited by 171
Platelet-Rich Plasma in Muscle Healing
Borrione, P., Gianfrancesco, A. D., Pereira, M. T., & Pigozzi, F. (2010) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3181f1c1c7 · Cited by 169
“Moreover, after experimental muscle damage, the delivery of adenoassociated viral -VEGF markedly promoted muscle fiber regeneration in a dose-dependent manner.(30)”
BackgroundInfluentialA CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis
Tremmel, M., Matzke, A., Albrecht, I., Laib, A. M., Olaku, V., Ballmer-Hofer, K., Christofori, G., Héroult, M., Augustin, H. G., Ponta, H., et al. (2009) · Blood · doi:10.1182/blood-2009-04-219204 · Cited by 170
Therapeutic application of anti-angiogenic nanomaterials in cancers
Mukherjee, S., & Patra, C. R. (2016) · Nanoscale · doi:10.1039/c5nr07887c · Cited by 169
Garrett, T. A., Van Buul, J. D., & Burridge, K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.027 · Cited by 164
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 202
“The binding of VEGFs and VEGFRs promotes the dimerization of receptors and is followed by intracellular approaching and activation of TK domains (Ferrara et al., 2003).”
BackgroundWhat tangled webs they weave: Rho-GTPase control of angiogenesis
Bryan, B. A., & D’Amore, P. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7008-z · Cited by 167
Muscle‐specific VEGF deficiency greatly reduces exercise endurance in mice
Olfert, I. M., Howlett, R. A., Tang, K., Dalton, N. D., Gu, Y., Peterson, K. L., Wagner, P. D., & Breen, E. C. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164384 · Cited by 166
“…with loxP sites) gene provides coding common to all VEGF isoforms (i.e. VEGF120, VEGF164, VEGF188, VEGF205, including the less frequent VEGF144, VEGF182) (Robinson & Stringer, 2001; Ferrara et al. 2003) and therefore the VEGF gene mutation in our mouse model results in loss of all VEGF-A isoforms.”
BackgroundChemotherapy for metastatic gastric cancer: past, present, and future
Ohtsu, A. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2177-6 · Cited by 168
“Agents targeting vascular endothelial growth factor pathways Vascular endothelial growth factor (VEGF) is one of the most potent proangiogenic growth factors; it is expressed in most solid tumors and tumor stromal cells and it presence correlates with advanced stage cancer and a poor prognosis.(29) Bevacizumab is a hu…”
Zhuang, Y., Zhang, C., Cheng, M., Huang, J., Liu, Q., Yuan, G., Lin, K., & Yu, H. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.11.028 · Cited by 163
Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis
Dasgupta, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.02.002 · Cited by 165
Glycosaminoglycan modification of neuropilin‐1 modulates VEGFR2 signaling
Shintani, Y., Takashima, S., Asano, Y., Kato, H., Liao, Y., Yamazaki, S., Tsukamoto, O., Seguchi, O., Yamamoto, H., Fukushima, T., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601188 · Cited by 167
“VEGFR2 is the primary receptor mediating the angiogenic activity of VEGF (Shalaby et al, 1995; Ferrara et al, 2003), and NRP1 functions as a co- receptor to enhance VEGFR2 signaling (Soker et al, 1998).”
BackgroundInfluentialEmerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases
Kandarakis, S. A., Piperi, C., Topouzis, F., & Papavassiliou, A. G. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.05.002 · Cited by 158
“Scientific evidence indicates that advanced glycation takes place in many cells and tissues that compose the visual system; this presents a common pathogenic factor in many disorders of the eye such as age-related macular degeneration (AMD), cataract and diabetic retinopathy (DR) (Stitt, 2005).”
BackgroundInfluentialVascular Endothelial Growth Factor: An Essential Component of Angiogenesis and Fracture Healing
Beamer, B., Hettrich, C., & Lane, J. (2010) · HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-009-9129-4 · Cited by 161
“The human VEGF gene undergoes alternative splicing to produce the four major cleavage products with the 165 amino acid peptide being the isoforms with the greatest biological activity [5].”
BackgroundA review of mathematical models for the formation of vascular networks
Scianna, M., Bell, C. G., & Preziosi, L. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.04.037 · Cited by 167
“These angiogenic factors, which are known to induce EC growth, survival, and motility [85, 192], can in fact bind to specific tyrosine”
BackgroundCascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Bergman Jungeström, M., Thompson, L. U., & Dabrosin, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1651 · Cited by 165
“The VEGF protein exists in several isoforms and is bioactive as soluble proteins in the extracellular space (13).”
BackgroundA sex-specific role for androgens in angiogenesis
Sieveking, D. P., Lim, P., Chow, R. W. Y., Dunn, L. L., Bao, S., McGrath, K. C. Y., Heather, A. K., Handelsman, D. J., Celermajer, D. S., & Ng, M. K. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091924 · Cited by 161
“As KDR is the chief mediator of the mitogenic/angiogenic action of VEGF in ECs, whereas Flt-1 may function as a negative regulator of VEGF action (Ferrara et al., 2003), our findings are consistent with a proangiogenic role for DHT through VEGF signaling via KDR.”
BackgroundBiomarkers in triple negative breast cancer: A review
Yadav, B. S., Chanana, P., & Jhamb, S. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.252 · Cited by 192
Signals in the pancreatic islet microenvironment influence β‐cell proliferation
Aamodt, K. I., & Powers, A. C. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13031 · Cited by 181
“early pancreatic epithelium remodels, it produces vascular endothelial growth factor A (VEGF-A), which binds VEGF receptors on endothelial cells, promoting endothelial migration and proliferation.(66)”
BackgroundKivelä, R., Hemanthakumar, K. A., Vaparanta, K., Robciuc, M., Izumiya, Y., Kidoya, H., Takakura, N., Peng, X., Sawyer, D. B., Elenius, K., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036099 · Cited by 162
Hesser, B. A., Liang, X. H., Camenisch, G., Yang, S., Lewin, D. A., Scheller, R., Ferrara, N., & Gerber, H.-P. (2004) · Blood · doi:10.1182/blood-2004-01-0273 · Cited by 168
Self-citationSuppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
Burton, J. B., Priceman, S. J., Sung, J. L., Brakenhielm, E., An, D. S., Pytowski, B., Alitalo, K., & Wu, L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1488 · Cited by 167
“Inhibition of VEGF signaling, by targeting either the ligand or the receptor, suppresses both tumor growth and metastasis and is currently being tested in clinical trials as single agents and in combination with chemotherapy or radiation therapy (6, 8, 9).”
Antibody-Targeted Nanoparticles for Cancer Therapy
Fay, F., & Scott, C. J. (2011) · Immunotherapy · doi:10.2217/imt.11.5 · Cited by 160
VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis
Tjwa, M., Luttun, A., Autiero, M., & Carmeliet, P. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0776-3 · Cited by 158
“Indeed, VEGFR-2 has been shown to signal VEGF-mediated mitogenic, chemotactic and prosurvival effects in cultured endothelial cells (ECs) (reviewed in Claesson-Welsh 2003; Ferrara et al. 2003).”
Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues
Chidlow, J. H., Shukla, D., Grisham, M. B., & Kevil, C. G. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00107.2007 · Cited by 167
“VEGF-C and -D are involved in lymphangiogenesis and are complementary to the roles of VEGF-A and -B, although their involvement in IBD is not yet entirely clear (47).”
BackgroundInfluentialGeometrically Controlled Endothelial Tubulogenesis in Micropatterned Gels
Raghavan, S., Nelson, C. M., Baranski, J. D., Lim, E., & Chen, C. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0584 · Cited by 160
PET and SPECT in cardiovascular molecular imaging
Dobrucki, L. W., & Sinusas, A. J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.201 · Cited by 164
“Angiogenesis is initiated by several local and circulating factors, including vascular endothelial growth factor (VEGF”
BackgroundCancer secretomics reveal pathophysiological pathways in cancer molecular oncology
Karagiannis, G. S., Pavlou, M. P., & Diamandis, E. P. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.09.001 · Cited by 159
Zhu, A. X., Finn, R. S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 159
“VEGF-A (hereafter referred to as VEGF) is a central regulator of endothelial cell proliferation and survival, tumor angiogenesis, and vascular permeability, which is thought to be primarily due to VEGFR-2 activation (4).”
BackgroundWang, J., Li, W., Lu, Z., Zhang, L., Hu, Y., Li, Q., Du, W., Feng, X., Jia, H., & Liu, B.-F. (2017) · Nanoscale · doi:10.1039/c7nr04425a · Cited by 164
Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy
TOZER, G. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.015 · Cited by 163
“These changes result in an increased production of pro-angiogenic, as opposed to anti-angiogenic, growth factors such as vascular endothelial growth factor (VEGF), which induce the proliferation and migration of vascular endothelial cells [1].”
BackgroundReview: Molecular pathogenesis of blood–brain barrier breakdown in acute brain injury
Nag, S., Kapadia, A., & Stewart, D. J. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01138.x · Cited by 161
Grisanti, S., & Tatar, O. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.002 · Cited by 165
“It can activate VEGFRs in a ligand-dependent manner by promoting the activation of mechanosensory complexes, which include platelet-endothelial-cell adhesion molecule-1 (PECAM1), vascular endothelial (VE)-cadherin, VEGFRs and integrins.”
BackgroundPeptide-Based Treatment: A Promising Cancer Therapy
Xiao, Y.-F., Jie, M.-M., Li, B.-S., Hu, C.-J., Xie, R., Tang, B., & Yang, S.-M. (2015) · Journal of Immunology Research · doi:10.1155/2015/761820 · Cited by 163
“Therefore, VEGFR1 and VEGFR2 are promising antiangiogenic targets [79].”
BackgroundImplications of vascular endothelial growth factor for postischemic neurovascular remodeling
Hermann, D. M., & Zechariah, A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.100 · Cited by 162
“Vascular endothelial growth factor receptor-2 mediates most of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF (Ferrara et al, 2003; see Table 1).”
BackgroundInfluentialIncreased Expression of Angiogenic Genes in the Brains of Mouse Meg3-Null Embryos
Gordon, F. E., Nutt, C. L., Cheunsuchon, P., Nakayama, Y., Provencher, K. A., Rice, K. A., Zhou, Y., Zhang, X., & Klibanski, A. (2010) · Endocrinology · doi:10.1210/en.2009-1151 · Cited by 160
“Expression changes of genes in the VEGF pathway, including Vegfa, Vegfr1, Neuropilin 1 (Nrp1), IQ motif containing GTPase activating protein 1 (Iqgap1), and Wiskott-Aldrich syndrome-like (Wasl), were examined by quantitative RT-PCR in eight Meg3null embryos and seven wild-type littermates from six lit- Biological proc…”
BackgroundInfluentialDragoni, S., Laforenza, U., Bonetti, E., Lodola, F., Bottino, C., Berra-Romani, R., Carlo Bongio, G., Cinelli, M. P., Guerra, G., Pedrazzoli, P., et al. (2011) · Stem Cells · doi:10.1002/stem.734 · Cited by 158
Emerging roles of RNA and RNA-binding protein network in cancer cells
Kim, M.-Y., Hur, J., & Jeong, S.-J. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.3.125 · Cited by 163
“However, they seem to have a different but coordinated ability for tumor vascularization (35, 36).”
BackgroundBäumer, S., Keller, L., Holtmann, A., Funke, R., August, B., Gamp, A., Wolburg, H., Wolburg-Buchholz, K., Deutsch, U., & Vestweber, D. (2006) · Blood · doi:10.1182/blood-2006-01-0141 · Cited by 158
Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 158
Headen, D. M., García, J. R., & García, A. J. (2018) · Microsystems & Nanoengineering · doi:10.1038/micronano.2017.76 · Cited by 159
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Tam, B. Y. Y., Wei, K., Rudge, J. S., Hoffman, J., Holash, J., Park, S.-K., Yuan, J., Hefner, C., Chartier, C., Lee, J.-S., et al. (2006) · Nature Medicine · doi:10.1038/nm1428 · Cited by 163
Nanogels for intracellular delivery of biotherapeutics
Li, D., van Nostrum, C. F., Mastrobattista, E., Vermonden, T., & Hennink, W. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.020 · Cited by 161
“Vascular endothelial growth factor (VEGF) is a protein that is essential for tumor growth, progression, and metastasis [158].”
Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants
Peattie, R. A., Nayate, A. P., Firpo, M. A., Shelby, J., Fisher, R. J., & Prestwich, G. D. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.09.054 · Cited by 161
Placental Growth Factor Promotes Atherosclerotic Intimal Thickening and Macrophage Accumulation
Khurana, R., Moons, L., Shafi, S., Luttun, A., Collen, D., Martin, J. F., Carmeliet, P., & Zachary, I. C. (2005) · Circulation · doi:10.1161/circulationaha.104.495887 · Cited by 158
Medford, A. R. L. (2006) · Thorax · doi:10.1136/thx.2005.040204 · Cited by 159
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors
Mitra, S. K., Mikolon, D., Molina, J. E., Hsia, D. A., Hanson, D. A., Chi, A., Lim, S.-T., Bernard-Trifilo, J. A., Ilic, D., Stupack, D. G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209588 · Cited by 158
“The formation of new blood vessels promoting tumor growth is termed angiogenesis and is controlled by the production and release of soluble factors, one of which is vascular endothelial growth factor (VEGF) (Hanahan and Weinberg, 2000; Ferrara et al., 2003).”
BackgroundEph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression
HEROULT, M., SCHAFFNER, F., & AUGUSTIN, H. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.028 · Cited by 160
Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
Meyer, T. V., Robles-Carrillo, L. D., Robson, T., Länger, F. P., DESAI, H., Davila, M., Amaya, M., Francis, J. L., & Amirkhosravi, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03212.x · Cited by 160
Intertwined regulation of angiogenesis and immunity by myeloid cells
Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158
Cortical Microvascular Remodeling in the Stenotic Kidney: Role of Increased Oxidative Stress
Zhu, X.-Y., Chade, A. R., Rodriguez-Porcel, M., Bentley, M. D., Ritman, E. L., Lerman, A., & Lerman, L. O. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000142443.52606.81 · Cited by 159
van der Veldt, A. A. M., Eechoute, K., Gelderblom, H. A. J., Gietema, J. A., Guchelaar, H., van Erp, N. P., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Mathijssen, R. H. J., & Wessels, J. A. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1828 · Cited by 172
“Particularly, genetic variation in VEGFR-2 may affect sunitinib activity, because VEGFR-2 is expressed in the normal endothelium (17) and the tumor vasculature may develop from preexisting vessels of the host (18).”
A review on angiogenesis and its assays.
Tahergorabi, Z., & Khazaei, M. (2012) · PubMed Central · Cited by 237
The Cutaneous Vascular System in Chronic Skin Inflammation
Huggenberger, R., & Detmar, M. J. (2011) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2011.5 · Cited by 169
“VEGF-A is probably the most important growth factor leading to blood and lymphatic vascular remodeling in psoriasis, and is currently the best-described inducer of inflammationdriven vascular remodeling (Detmar et al., 1994; Ferrara et al., 2003).”
BackgroundPlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 163
“VEGF-A binds two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) (Ferrara et al., 2003).”
Self-citationSystemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis
Schonthaler, H. B., Huggenberger, R., Wculek, S. K., Detmar, M., & Wagner, E. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907550106 · Cited by 160
“VEGF induces hyperpermeability of blood vessels, leading to tissue edema during inflammation (42).”
BackgroundAngiogenesis and liver fibrosis
Elpek, G. Ö. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.377 · Cited by 175
Liu, T., Ma, W., Xu, H., Huang, M., Zhang, D., He, Z., Zhang, L., Brem, S., O’Rourke, D. M., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05982-z · Cited by 151
Small molecule recognition of disease-relevant RNA structures
Meyer, S. M., Williams, C. C., Akahori, Y., Tanaka, T., Aikawa, H., Tong, Y., Childs-Disney, J. L., & Disney, M. D. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00560f · Cited by 160
Kaira, K., Oriuchi, N., Imai, H., Shimizu, K., Yanagitani, N., Sunaga, N., Hisada, T., Tanaka, S., Ishizuka, T., Kanai, Y., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00969.x · Cited by 155
Seto, T., Higashiyama, M., Funai, H., Imamura, F., Uematsu, K., Seki, N., Eguchi, K., Yamanaka, T., & Ichinose, Y. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.02.009 · Cited by 160
Nagineni, C. N., Kommineni, V. K., William, A., Detrick, B., & Hooks, J. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22708 · Cited by 150
Molecular aspects of tumour hypoxia
Rademakers, S. E., Span, P. N., Kaanders, J. H. A. M., Sweep, F. C. G. J., van der Kogel, A. J., & Bussink, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.03.006 · Cited by 187
The Effect of Exercise on the Prevention of Osteoporosis and Bone Angiogenesis
Tong, X., Chen, X., Zhang, S., Huang, M., Shen, X., Xu, J., & Zou, J. (2019) · BioMed Research International · doi:10.1155/2019/8171897 · Cited by 149
“VEGFs are abundantly expressed and play an important role in the proliferation, migration, and activation of endothelial cells, as well as in angiogenesis [63, 64].”
BackgroundAngiogenic inhibition reduces germinal matrix hemorrhage
Ballabh, P., Xu, H., Hu, F., Braun, A., Smith, K. E., Rivera, A., Lou, N., Ungvari, Z. I., Goldman, S. A., Csiszár, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1558 · Cited by 163
“VEGF, the predominant angiogenic growth factor of development, triggers endothelial cell proliferation, migration and increased vascular permeability attending the formation of nascent vessels, which essentially consist of immature endothelium with few pericytes and little mature matri”
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.